Find the Vulnerabilities Before FDA Does: 2026 MedTech Cybersecurity Trends

Since Section 524B of the FD&C Act took effect, cybersecurity is a gate to market, not a postmarket afterthought. FDA can now refuse to accept a premarket submission for a connected device that arrives without a threat model, a maintained software bill of materials, and evidence of security testing.

The risk behind that rule is real: as of January 2022, an estimated 53% of connected medical devices in hospitals already carried a known critical vulnerability. The teams that clear review on the first pass are the ones that find those gaps before an FDA reviewer, or an attacker, does.

Inside you’ll discover:

• The 2026 threat and regulatory landscape for connected devices, in plain operating terms
• What FDA now expects inside the submission: threat model, SBOM, penetration testing, and postmarket vulnerability plan
• The three places teams predictably lose six months to avoidable hold letters, and how to avoid each one
• A step-by-step submission-readiness playbook with a worked example
• A side-by-side view of FDA Section 524B versus EU MDR and MDCG 2019-16 expectations

Nicholas Butt, Practice Lead for Cybersecurity and head of Avania’s Sentinel service, with Acacia Parks, PhD, MBA, RAC, VP of Quality & Compliance. Avania pairs more than 25 years of FDA regulatory strategy with hands-on device security engineering, so security evidence is built in and submission-ready across both the US and the EU, not bolted on at the end.Security evidence built in, not bolted on. That’s what MedTech’s Trusted Champion looks like in practice.and submission-ready across both the US and the EU, not bolted on at the end.

Want a deeper look at your own program? You can also request a 524B readiness review or a scoped penetration test at avaniaclinical.com/contact-us.